Innovative treatment approaches include pharmacotherapy for patients with PTPR with specific mutations, including a patient with PTPR with PTEN R130Q chromosome 10 loss treated with everolimus monotherapy who experienced continuous tumor regression over 27 months and had been stable for 43 months at the time of publication [23]. The gene discussed is PTPRR; the disease is neoplasm.